Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc (NASDAQ: ABEO) is a clinical-stage biopharmaceutical leader advancing gene therapies for rare genetic diseases. This dedicated news hub provides investors and researchers with essential updates on ABEO’s therapeutic developments, regulatory milestones, and scientific partnerships.
Discover timely press releases detailing progress in AAV-based therapies, CRISPR/Cas9 research, and pivotal clinical trials for conditions like epidermolysis bullosa. Our curated collection includes FDA correspondence updates, manufacturing quality certifications, and strategic collaboration announcements – all critical for evaluating the company’s trajectory.
Key content categories feature BLA submission statuses, Phase 3 trial results, and technology licensing agreements. Bookmark this page for streamlined access to verified updates about ABEO’s pipeline candidates and operational developments, presented with clarity for both professional analysts and engaged stakeholders.
Abeona Therapeutics Inc. (Nasdaq: ABEO) reported significant changes in its leadership as CEO João Siffert, M.D. resigned, along with several board members on September 23 and 27, 2020. The company is now evaluating strategic options, including potential asset sales, although no specific timeline or outcomes are guaranteed. Abeona specializes in gene and cell therapies for serious diseases, with ongoing clinical programs in Phase 1/2 and Phase 3 development. The company highlights its AAV-based gene therapies and GMP manufacturing capabilities, essential for its clinical trials.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced its participation in key investor conferences in September 2020. CEO João Siffert will engage in virtual one-on-one meetings at Citi’s 15th Annual BioPharma Virtual Conference on September 9. Additionally, he will present at the Wells Fargo Virtual Healthcare Conference on September 10 at 10:00 a.m. ET, with a live webcast available on Abeona’s website. Abeona focuses on gene and cell therapies for serious diseases, including programs for recessive dystrophic epidermolysis bullosa and Sanfilippo syndrome.
Abeona Therapeutics Inc. (Nasdaq: ABEO) and Taysha Gene Therapies have entered into agreements for the licensing and purchase of inventory related to ABO-202, a gene therapy for CLN1 disease, also known as infantile Batten disease. Taysha will pay Abeona $7 million upfront, plus potential milestone payments up to $56 million and royalties on sales. The therapy aims to deliver a functional copy of the PPT1 gene, addressing a critical unmet medical need. Abeona will focus on advancing its other clinical programs post-agreement.
Abeona Therapeutics (Nasdaq: ABEO) reported significant clinical advancements and financial results for Q2 2020. The firm resumed patient enrollment in pivotal studies for RDEB and MPS IIIA, with new patients treated in both programs. Abeona aims for a 2023 EU marketing application for ABO-102 and anticipates commercial launches of EB-101 in late-2022. Financially, the company held $107.9 million in cash, with a net loss of $13 million for Q2. Leadership strengthened with a new Chief Commercial Officer and board members, enhancing strategic direction.
Abeona Therapeutics announced results from two poster presentations at the Society for Pediatric Dermatology's Annual Meeting regarding its EB-101 treatment for recessive dystrophic epidermolysis bullosa (RDEB). The data revealed that EB-101 treatment led to significant and durable healing of large, chronic wounds, resulting in long-term pain relief lasting up to five years. Additionally, a literature review of 65 studies highlighted the substantial clinical, economic, and humanistic burden associated with RDEB, affecting patients and their families.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Michael Amoroso as the new Senior Vice President and Chief Commercial Officer, effective immediately. With over 20 years of experience in biotechnology and pharmaceuticals, Amoroso aims to lead the company's commercial strategies for its gene therapies, including the pivotal Phase 3 study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). His previous roles at Kite and other major firms equip him with expertise in product commercialization, essential for Abeona’s growth and market strategy.
Abeona Therapeutics (Nasdaq: ABEO) announced the resumption of patient enrollment in the pivotal Phase 3 VIITAL™ study of EB-101, a gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). Enrollment was paused due to COVID-19, impacting healthcare resources.
Additionally, the ongoing MPS III Phase 1/2 clinical trials for gene therapies ABO-102 and ABO-101 continue to treat patients, with recent dosing updates. Abeona’s gene therapies address critical unmet needs in rare diseases, with EB-101 showing durable wound healing from a previous Phase 1/2 trial.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced two abstracts for its clinical program on recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the Society for Pediatric Dermatology's Annual Meeting from July 10-12, 2020. RDEB is a rare disorder causing severe skin wounds, with no approved treatments available. The first abstract discusses long-term pain relief from EB-101 treatment, while the second reviews the overall burden of RDEB. Presenters include Stanford University’s Jean Tang and M. Peter Marinkovich. Detailed information will be accessible on Abeona's website post-event.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the appointment of George Migausky and Paul Mann as independent directors, effective June 17, 2020. Migausky will also serve as Chairman of the Audit Committee, enhancing the company’s governance. With over 30 years of experience in financial management and strong backgrounds in biotechnology, both directors will contribute to the advancement of Abeona's gene and cell therapies. Notable projects include EB-101, in Phase 3 development, and ABO-102 and ABO-101 for Sanfilippo syndrome, aimed at addressing urgent medical needs.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that its CEO, João Siffert, M.D., will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 10:00 a.m. ET. The live webcast can be accessed on the company's investor website, with a replay available within 24 hours for 90 days. Abeona focuses on gene and cell therapies for serious diseases, including EB-101 for epidermolysis bullosa and AAV-based therapies for Sanfilippo syndrome. The company has received multiple regulatory designations from the FDA and EMA, signaling its innovative pipeline.
